Dr. Reddy's Laboratories Limited (DRREDDY.BO)
INR 1108.55
(1.83%)
INR 1108.55
(1.83%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 106.96 Billion INR | 18.87% |
| 2022 | 89.99 Billion INR | -15.21% |
| 2021 | 106.12 Billion INR | 17.25% |
| 2020 | 90.51 Billion INR | 17.16% |
| 2019 | 77.25 Billion INR | -9.36% |
| 2018 | 85.23 Billion INR | -14.03% |
| 2017 | 99.14 Billion INR | 3.52% |
| 2016 | 95.77 Billion INR | 20.76% |
| 2015 | 79.31 Billion INR | -4.97% |
| 2014 | 83.46 Billion INR | 5.08% |
| 2013 | 79.42 Billion INR | -88.53% |
| 2012 | 692.64 Billion INR | 1016.58% |
| 2011 | 62.03 Billion INR | 26.56% |
| 2010 | 49.01 Billion INR | 31.0% |
| 2009 | 37.41 Billion INR | -10.38% |
| 2008 | 41.74 Billion INR | 8.78% |
| 2007 | 38.37 Billion INR | -13.63% |
| 2006 | 44.43 Billion INR | -4.68% |
| 2005 | 46.61 Billion INR | 459.27% |
| 2004 | 8.33 Billion INR | 49.05% |
| 2003 | 5.59 Billion INR | 31.65% |
| 2002 | 4.24 Billion INR | 21.16% |
| 2001 | 3.5 Billion INR | -46.9% |
| 2000 | 6.6 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 120.67 Billion INR | 12.81% |
| 2024 Q2 | 156.67 Billion INR | 29.84% |
| 2023 Q1 | 89.78 Billion INR | -0.23% |
| 2023 Q4 | 106.96 Billion INR | 1.88% |
| 2023 Q3 | 104.99 Billion INR | 11.77% |
| 2023 Q2 | 93.93 Billion INR | 4.63% |
| 2023 FY | 106.96 Billion INR | 18.87% |
| 2022 Q2 | 84.74 Billion INR | -11.34% |
| 2022 Q1 | 95.58 Billion INR | -9.93% |
| 2022 FY | 89.99 Billion INR | -15.21% |
| 2022 Q4 | 89.99 Billion INR | 1.08% |
| 2022 Q3 | 89.02 Billion INR | 5.05% |
| 2021 FY | 106.12 Billion INR | 17.25% |
| 2021 Q4 | 106.12 Billion INR | 14.75% |
| 2021 Q3 | 92.48 Billion INR | -2.21% |
| 2021 Q2 | 94.57 Billion INR | -5.52% |
| 2021 Q1 | 100.1 Billion INR | 10.6% |
| 2020 FY | 90.51 Billion INR | 17.16% |
| 2020 Q3 | 82.95 Billion INR | -5.78% |
| 2020 Q2 | 88.04 Billion INR | -1.63% |
| 2020 Q4 | 90.51 Billion INR | 9.11% |
| 2020 Q1 | 89.49 Billion INR | 15.85% |
| 2019 FY | 77.25 Billion INR | -9.36% |
| 2019 Q1 | 80.88 Billion INR | -5.1% |
| 2019 Q2 | 80.04 Billion INR | -1.03% |
| 2019 Q4 | 77.25 Billion INR | 11.6% |
| 2019 Q3 | 69.22 Billion INR | -13.52% |
| 2018 Q3 | 90.96 Billion INR | -11.5% |
| 2018 FY | 85.23 Billion INR | -14.03% |
| 2018 Q2 | 102.78 Billion INR | 2.33% |
| 2018 Q1 | 100.45 Billion INR | 1.32% |
| 2018 Q4 | 85.23 Billion INR | -6.31% |
| 2017 FY | 99.14 Billion INR | 3.52% |
| 2017 Q4 | 99.14 Billion INR | -3.06% |
| 2017 Q3 | 102.27 Billion INR | 2.09% |
| 2017 Q2 | 100.17 Billion INR | 5.49% |
| 2017 Q1 | 94.96 Billion INR | -0.85% |
| 2016 Q3 | 106.14 Billion INR | 0.95% |
| 2016 FY | 95.77 Billion INR | 20.76% |
| 2016 Q1 | 81.41 Billion INR | 2.65% |
| 2016 Q2 | 105.15 Billion INR | 29.16% |
| 2016 Q4 | 95.77 Billion INR | -9.77% |
| 2015 Q1 | 82.31 Billion INR | -1.37% |
| 2015 FY | 79.31 Billion INR | -4.97% |
| 2015 Q2 | 80.98 Billion INR | -1.61% |
| 2015 Q4 | 79.31 Billion INR | 0.14% |
| 2015 Q3 | 79.2 Billion INR | -2.21% |
| 2014 Q4 | 83.46 Billion INR | 5.26% |
| 2014 FY | 83.46 Billion INR | 5.08% |
| 2014 Q2 | 77.31 Billion INR | 0.65% |
| 2014 Q1 | 76.81 Billion INR | -3.28% |
| 2014 Q3 | 79.29 Billion INR | 2.56% |
| 2013 Q2 | 83.06 Billion INR | 9.46% |
| 2013 Q1 | 75.88 Billion INR | -89.04% |
| 2013 Q4 | 79.42 Billion INR | -4.25% |
| 2013 Q3 | 82.95 Billion INR | -0.13% |
| 2013 FY | 79.42 Billion INR | -88.53% |
| 2012 Q2 | 67.34 Billion INR | 0.56% |
| 2012 Q4 | 692.64 Billion INR | 889.18% |
| 2012 FY | 692.64 Billion INR | 1016.58% |
| 2012 Q3 | 70.02 Billion INR | 3.98% |
| 2012 Q1 | 66.97 Billion INR | 7.96% |
| 2011 FY | 62.03 Billion INR | 26.56% |
| 2011 Q3 | 70.5 Billion INR | 18.05% |
| 2011 Q4 | 62.03 Billion INR | -12.01% |
| 2011 Q2 | 59.72 Billion INR | 21.76% |
| 2011 Q1 | 49.04 Billion INR | 0.07% |
| 2010 Q2 | 38.12 Billion INR | 3.32% |
| 2010 Q1 | 36.89 Billion INR | -1.38% |
| 2010 Q3 | 35.87 Billion INR | -5.91% |
| 2010 Q4 | 49.01 Billion INR | 36.65% |
| 2010 FY | 49.01 Billion INR | 31.0% |
| 2009 Q2 | 37.02 Billion INR | 17.94% |
| 2009 Q3 | 32.08 Billion INR | -13.35% |
| 2009 Q4 | 37.41 Billion INR | 16.62% |
| 2009 Q1 | 31.39 Billion INR | -24.79% |
| 2009 FY | 37.41 Billion INR | -10.38% |
| 2008 Q1 | 41.7 Billion INR | 8.66% |
| 2008 Q2 | 45.87 Billion INR | 10.01% |
| 2008 Q3 | 44.49 Billion INR | -3.02% |
| 2008 Q4 | 41.74 Billion INR | -6.17% |
| 2008 FY | 41.74 Billion INR | 8.78% |
| 2007 Q4 | 38.37 Billion INR | 8.99% |
| 2007 Q2 | 35.56 Billion INR | 1.12% |
| 2007 Q1 | 35.17 Billion INR | -20.85% |
| 2007 FY | 38.37 Billion INR | -13.63% |
| 2007 Q3 | 35.21 Billion INR | -1.0% |
| 2006 Q2 | 56.36 Billion INR | 5.28% |
| 2006 Q4 | 44.43 Billion INR | -8.45% |
| 2006 Q3 | 48.53 Billion INR | -13.89% |
| 2006 FY | 44.43 Billion INR | -4.68% |
| 2006 Q1 | 53.53 Billion INR | 14.85% |
| 2005 FY | 46.61 Billion INR | 459.27% |
| 2005 Q2 | 9.83 Billion INR | 2.43% |
| 2005 Q4 | 46.61 Billion INR | 350.85% |
| 2005 Q3 | 10.33 Billion INR | 5.09% |
| 2005 Q1 | 9.6 Billion INR | 15.25% |
| 2004 Q1 | 7.88 Billion INR | 40.93% |
| 2004 Q4 | 8.33 Billion INR | 31.99% |
| 2004 FY | 8.33 Billion INR | 49.05% |
| 2004 Q2 | 6.57 Billion INR | -16.53% |
| 2004 Q3 | 6.31 Billion INR | -4.0% |
| 2003 Q2 | 4.96 Billion INR | 7.8% |
| 2003 Q3 | 4.82 Billion INR | -2.76% |
| 2003 FY | 5.59 Billion INR | 31.65% |
| 2003 Q4 | 5.59 Billion INR | 15.89% |
| 2003 Q1 | 4.6 Billion INR | 8.38% |
| 2002 Q3 | 4.06 Billion INR | 3.76% |
| 2002 Q1 | 4.17 Billion INR | 19.11% |
| 2002 Q2 | 3.91 Billion INR | -6.16% |
| 2002 Q4 | 4.24 Billion INR | 4.47% |
| 2002 FY | 4.24 Billion INR | 21.16% |
| 2001 Q4 | 3.5 Billion INR | -0.98% |
| 2001 FY | 3.5 Billion INR | -46.9% |
| 2001 Q2 | 3.56 Billion INR | -6.96% |
| 2001 Q1 | 3.83 Billion INR | 0.0% |
| 2001 Q3 | 3.54 Billion INR | -0.71% |
| 2000 FY | 6.6 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | -557.302% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 29.722% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -1964.661% |
| Granules India Limited | 22.95 Billion INR | -366.003% |
| Indoco Remedies Limited | 10.34 Billion INR | -934.277% |
| Achyut Healthcare Limited | 2.01 Million INR | -5313759.911% |
| Ajanta Pharma Limited | 10.71 Billion INR | -898.74% |
| Alkem Laboratories Limited | 48.6 Billion INR | -120.076% |
| Alpa Laboratories Limited | 307.12 Million INR | -34729.156% |
| Brooks Laboratories Limited | 248.6 Million INR | -42927.985% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -2821.738% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -2097.52% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -4972.336% |
| Eris Lifesciences Limited | 38.26 Billion INR | -179.523% |
| FDC Limited | 3.7 Billion INR | -2783.85% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | -64.286% |
| Gufic Biosciences Limited | 5.59 Billion INR | -1810.208% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -4572.191% |
| Ipca Laboratories Limited | 33.74 Billion INR | -217.01% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -35945.289% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -3496.876% |
| Lasa Supergenerics Limited | 541.92 Million INR | -19638.525% |
| Laurus Labs Limited | 42.71 Billion INR | -150.425% |
| Lupin Limited | 96.23 Billion INR | -11.15% |
| Mankind Pharma Limited | 23.87 Billion INR | -348.04% |
| Medicamen Biotech Limited | 940.36 Million INR | -11275.133% |
| Medico Remedies Limited | 438.24 Million INR | -24308.32% |
| Megasoft Limited | 1.85 Billion INR | -5672.247% |
| NATCO Pharma Limited | 10.53 Billion INR | -915.648% |
| Piramal Pharma Limited | 74 Billion INR | -44.543% |
| RPG Life Sciences Limited | 1.38 Billion INR | -7650.181% |
| Sigachi Industries Limited | 2.53 Billion INR | -4125.871% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 41.729% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -5158.405% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -9080.14% |
| Unichem Laboratories Limited | 8.06 Billion INR | -1225.625% |
| Wanbury Limited | 3.15 Billion INR | -3289.872% |
| Windlas Biotech Limited | 1.76 Billion INR | -5968.418% |
| ZIM Laboratories Limited | 2.08 Billion INR | -5040.809% |
| Zydus Lifesciences Limited | 71.79 Billion INR | -48.997% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -2647.772% |
| Divi's Laboratories Limited | 18.99 Billion INR | -463.286% |
| Hester Biosciences Limited | 3.59 Billion INR | -2875.698% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -4076.48% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -13546.941% |
| Bal Pharma Limited | 2.51 Billion INR | -4159.508% |
| Strides Pharma Science Limited | 37.68 Billion INR | -183.882% |
| Venus Remedies Limited | 1.39 Billion INR | -7580.069% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -1196.472% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -853.532% |
| Shilpa Medicare Limited | 12.93 Billion INR | -727.127% |
| Aarti Drugs Limited | 11.5 Billion INR | -829.833% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -1590.152% |
| Suven Life Sciences Limited | 148.62 Million INR | -71873.678% |
| Ind-Swift Limited | 13.45 Billion INR | -695.126% |
| Valiant Laboratories Limited | 1.05 Billion INR | -10007.923% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -898.954% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | -656.289% |
| Themis Medicare Limited | 1.88 Billion INR | -5567.146% |
| Hikal Limited | 12.99 Billion INR | -723.154% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | -30.369% |
| Sequent Scientific Limited | 8.27 Billion INR | -1192.782% |
| Novartis India Limited | 1.8 Billion INR | -5839.037% |
| Wockhardt Limited | 39.87 Billion INR | -168.292% |
| Jubilant Pharmova Limited | 61.27 Billion INR | -74.573% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -36938.909% |
| Neuland Laboratories Limited | 5.49 Billion INR | -1845.381% |
| Morepen Laboratories Limited | 4.45 Billion INR | -2298.499% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -16512.956% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -5312.508% |